TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: Even for patients with ALCL, whose outcomes are better than CD30-negative PTCL due to the ability to target CD30 with brentuximab vedotin, long-term data demonstrates increased risk of relapse at 5-years [8, 9].